RxDoctor Payments Data

Carlos Munoz, MD

Family Medicine · Richmond, TXNPI 1043269285

Payments from drug & device makers

$18,178in general payments, 2019–2025

Across 1,119 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • Amgen$860
  • plus $9K from 52 others

What the payments were for

  • Food & beverage$18,07699%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)157$2,006
Novo Nordisk113$1,919
AstraZeneca92$1,884
Lilly USA, LLC92$1,461
Boehringer Ingelheim73$1,159
Amgen(2 entities)51$860
GSK50$825
Bayer45$747
Amarin Pharma, Inc.47$725
Nestle Healthcare Nutrition Inc.33$635
Pfizer40$570
Merck43$528
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC36$496
Johnson & Johnson24$369
Novartis30$345
Optinose US, Inc.14$329
Aimmune Therapeutics, Inc.14$323
Kowa Pharmaceuticals America, Inc.17$307
Sanofi-aventis U.S. LLC18$270
Otsuka America Pharmaceutical, Inc.9$185
Dexcom, Inc.7$173
Lundbeck LLC7$161
Sunovion Pharmaceuticals Inc.9$142
IBSA Pharma Inc.8$125
Esperion Therapeutics, Inc.7$121
Biohaven Pharmaceutical Holding Company Ltd.7$108
Shield Therapeutics Inc6$101
Vivus LLC5$97
Antares Pharma, Inc.5$86
Exact Sciences5$86
Sumitomo Pharma America, Inc.4$85
Eisai Inc.4$67
Takeda Pharmaceuticals U.S.A., Inc.4$66
E.r. Squibb & Sons, L.L.C.3$65
Althera Pharmaceuticals LLC4$65
Tactile Systems Technology Inc2$59
Astellas Pharma US Inc4$59
Biohaven Pharmaceuticals, Inc.3$52
Halozyme Inc2$41
Genentech USA, Inc.2$40
Mylan Specialty L.p.1$38
Paratek Pharmaceuticals, Inc.2$34
Phathom Pharmaceuticals, Inc.1$34
Endo Pharmaceuticals Inc.2$32
Tolmar, Inc.2$31
Avanir Pharmaceuticals, Inc.2$31
Gilead1$27
Scpharmaceuticals Inc.1$23
Avadel Specialty Pharmaceuticals, LLC1$23
Melinta Therapeutics, LLC2$22
Indivior Inc.1$21
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$20
Scilex Pharmaceuticals Inc.1$20
MDD US Operations, LLC1$19
Arbor Pharmaceuticals, Inc.1$18
Inspire Medical Systems, Inc.1$15
Idorsia Pharmaceuticals US Inc1$14
Teva Pharmaceuticals USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,178 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$59,455
Medicare patients
231
Services billed
741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide334$324,529
MounjaroTirzepatide182$203,258
EliquisApixaban196$124,634
FarxigaDapagliflozin Propanediol127$104,042
JardianceEmpagliflozin99$88,585
RybelsusSemaglutide68$76,857
Tresiba Flextouch U-200Insulin Degludec47$64,281
Xigduo XrDapaglifloz Propaned/Metformin94$54,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$47,724
Synjardy XrEmpagliflozin/Metformin Hcl75$47,719
TrulicityDulaglutide36$38,671
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog48$37,908
XareltoRivaroxaban47$37,122
Soliqua 100-33Insulin Glargine/Lixisenatide34$36,339
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog36$35,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,919$401,386402 claims
Lilly USA, LLCMounjaro, Trulicity$1,461$241,929218 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$1,159$153,776191 claims
PfizerEliquis$570$124,634196 claims
AstraZenecaFarxiga, Brilinta$1,884$112,296144 claims
MerckJanumet Xr, Januvia, Janumet, Lagevrio (Eua)$528$83,33595 claims
GSKTrelegy Ellipta$825$47,72474 claims
AbbVieCreon, Linzess, Savella$2,006$39,92336 claims
Johnson & JohnsonXarelto$369$37,12247 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$270$36,33934 claims
AmgenProlia$860$30,70718 claims
Astellas Pharma US IncMyrbetriq$59$22,29740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Richmond

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →